西伯利亚落叶松黄酮 | 53472-37-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 中文名称: 西伯利亚落叶松黄酮
• 英文名称: myricetin-5'-O-methyl ether
• 英文别名: myricetin 3'-methyl ether；Myricetin-3'-methylether；3'-O-methylmyricetin；laricitrin；laricytrin；larycitrin；2-(3,4-dihydroxy-5-methoxyphenyl)-3,5,7-trihydroxychromen-4-one
• CAS: 53472-37-0
• 化学式: C₁₆H₁₂O₈
• 分子量: 332.266
• InChiKey: CFYMYCCYMJIYAB-UHFFFAOYSA-N

物化性质

• 沸点：
  667.4±55.0 °C(Predicted)
• 密度：
  1.730±0.06 g/cm3(Predicted)
• LogP：
  1.900 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  137
• 氢给体数：
  5
• 氢受体数：
  8

安全信息

• 海关编码：
  2914509090

反应信息

• 作为产物：
  描述：

  杨梅素 、 alkaline earth salt of/the/ methylsulfuric acid 在 DL-dithiothreitol 、 HCl buffer 、 三羟甲基氨基甲烷 作用下， 反应 1.0h， 生成 西伯利亚落叶松黄酮
  参考文献：
  名称：

  来自水稻的类黄酮 3'-O-甲基转移酶：cDNA 克隆、表征和功能表达

  摘要：

  已知植物 O-甲基转移酶 (OMT) 参与植物次生代谢物的甲基化，尤其是苯丙烷和类黄酮化合物。使用逆转录聚合酶链反应 (RT-PCR) 从水稻中克隆并表征了 OMT，ROMT-9。ROMT-9 的爆炸结果显示与来自玉米和普通小麦的咖啡酸 OMT 具有 73% 的同一性。ROMT-9 在大肠杆菌中表达，其重组蛋白使用亲和层析纯化。然后测试其将 S-腺苷-l-甲硫氨酸的甲基转移到类黄酮底物、圣草酚、木犀草素、槲皮素和紫杉叶素的能力，所有这些都具有 3'-羟基官能团。使用TLC、HPLC、HPLC/MS和NMR光谱分析反应产物。核磁共振分析表明，ROMT-9 将甲基特异性转移到槲皮素的 3'-羟基上，从而形成其甲氧基衍生物。此外，ROMT-9 将含有 3'-羟基官能团的黄酮类化合物如圣草酚、木犀草素、槲皮素和紫杉叶素转化为相应的甲氧基衍生物，表明 ROMT-9 是一种对黄酮类化合物的 3'-羟基具有严格特异性的

  DOI：

  10.1016/j.phytochem.2005.11.022

文献信息

• Composition for inhibiting formation of SNARE complex, containing myricetin derivatives
  申请人：RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY

  公开号：US10682333B2

  公开（公告）日：2020-06-16

  The present invention relates to a composition for inhibiting the formation of a SNARE complex, containing myricetin derivatives, and having novel structures and obtained by the acylation of myricetin, laricitrin, combretol, or syringetin. The myricetin derivatives are considered to exhibit an effect of being bioconverted into myricetin in a cell. The myricetin derivatives lost the dark color of conventional myricetin and properties thereof were changed such that the myricetin derivatives have properties of photostability and fat solubility. Therefore, since stable form myricetin derivatives are absorbed into a cell such that an activity, possessed by normal myricetin, of inhibiting the formation of a SNARE complex are exhibited, the present invention can exhibit an excellent function as a SNARE targeting prodrug, and as a composition for inhibiting the formation of a SNARE complex, containing the same.

  本发明涉及一种抑制 SNARE 复合物形成的组合物，该组合物含有米果黄素衍生物，具有新颖的结构，由米果黄素、laricitrin、combretol 或 syringetin酰化获得。这些杨梅素衍生物被认为具有在细胞中生物转化为杨梅素的效果。这种杨梅素衍生物失去了传统杨梅素的深色，其性质也发生了变化，使杨梅素衍生物具有光稳定性和脂溶性。因此，由于稳定形式的水杨梅素衍生物可被细胞吸收，从而显示出普通水杨梅素所具有的抑制 SNARE 复合物形成的活性，因此本发明作为 SNARE 靶向原药和抑制 SNARE 复合物形成的组合物，可发挥出色的功能。
• Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
  申请人：Auransa Inc.

  公开号：US10806716B2

  公开（公告）日：2020-10-20

  This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

  本公开提供了减少或消除心脏毒性，特别是由癌症治疗或其他疗法引起的心脏毒性的方法和药物组合物。在某些情况下，这些方法和组合物可以预防或减少蒽环类药物治疗引起的心脏毒性。本文提供的方法通常包括在施用抗癌药物或其他疗法的同时施用一种保护剂，如麦角黄素、三黄素、洋槐黄素、黄荆素、槲皮素、二氢洋槐黄素、山柰酚、7,3′,4′,5′-四羟基黄酮和麦角黄素。它们可以包括将保护剂与右雷佐生联合使用。本文提供的组合物包括一种保护剂与另一种保护剂或与一种癌症治疗药物（如蒽环类药物）的共同制剂。
• COMPOSITION FOR INHIBITING FORMATION OF SNARE COMPLEX, CONTAINING MYRICETIN DERIVATIVES
  申请人：iNtRON Biotechnology, Inc.

  公开号：EP3329913B1

  公开（公告）日：2021-11-10
• Ragunathan; Kumar, K. Mohan; Sankar, Asian Journal of Chemistry, 2011, vol. 23, # 6, p. 2819 - 2820
  作者：Ragunathan、Kumar, K. Mohan、Sankar

  DOI：——

  日期：——
• PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COUNTERING CHEMOTHERAPY INDUCED CARDIOTOXICITY
  申请人：Stem Cell Theranostics, Inc.

  公开号：US20170224654A1

  公开（公告）日：2017-08-10

  This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).